{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:39:37Z","timestamp":1783982377179,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81970276"],"award-info":[{"award-number":["No. 81970276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05466-1","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:33:20Z","timestamp":1766871200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Conghui","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"issue":"12","key":"5466_CR1","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"key":"5466_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.","journal-title":"J Immunother Cancer"},{"key":"5466_CR3","doi-asserted-by":"publisher","first-page":"107223","DOI":"10.1016\/j.vph.2023.107223","volume":"153","author":"S Barachini","year":"2023","unstructured":"Barachini S, et al. Antineoplastic drugs inducing cardiac and vascular toxicity - An update. Vascul Pharmacol. 2023;153:107223.","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"5466_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jch.14688","volume":"25","author":"M Karakayali","year":"2023","unstructured":"Karakayali M, et al. The relationship between the systemic immune-inflammation index and reverse-dipper circadian pattern in newly diagnosed hypertensive patients. J Clin Hypertens (Greenwich Conn). 2023;25(8):700\u20137.","journal-title":"J Clin Hypertens (Greenwich Conn)"},{"issue":"7","key":"5466_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41440-022-00941-0","volume":"45","author":"S Hoshide","year":"2022","unstructured":"Hoshide S, Mogi M, Kario K. Current status of hypertension and treatment in Asia. Hypertens Research: Official J Japanese Soc Hypertens. 2022;45(7):1095\u20136.","journal-title":"Hypertens Research: Official J Japanese Soc Hypertens"},{"issue":"8","key":"5466_CR6","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1097\/HJH.0000000000004065","volume":"43","author":"W Zhang","year":"2025","unstructured":"Zhang W, et al. Blood pressure-lowering efficacy of Sacubitril\/Allisartan versus Olmesartan in Chinese hypertensive patients with a nondipping blood pressure pattern. J Hypertens. 2025;43(8):1416\u201322.","journal-title":"J Hypertens"},{"issue":"3","key":"5466_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","volume":"14","author":"DJ Campbell","year":"2016","unstructured":"Campbell DJ. Long-term Neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol. 2016;14(3):171\u201386.","journal-title":"Nat Rev Cardiol"},{"key":"5466_CR8","doi-asserted-by":"publisher","first-page":"106303","DOI":"10.1016\/j.phrs.2022.106303","volume":"182","author":"C Sardu","year":"2022","unstructured":"Sardu C, et al. Angiotensin receptor\/Neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside. Pharmacol Res. 2022;182:106303.","journal-title":"Pharmacol Res"},{"issue":"2","key":"5466_CR9","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ehf2.14646","volume":"11","author":"H Liu","year":"2024","unstructured":"Liu H, et al. Improved heart function and cardiac remodelling following sacubitril\/valsartan in acute coronary syndrome with HF. ESC Heart Fail. 2024;11(2):937\u201349.","journal-title":"ESC Heart Fail"},{"issue":"9","key":"5466_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jcmg.2022.03.019","volume":"15","author":"M-G Moon","year":"2022","unstructured":"Moon M-G, et al. Reverse remodeling assessed by left atrial and ventricular strain reflects treatment response to Sacubitril\/Valsartan. JACC Cardiovasc Imaging. 2022;15(9):1525\u201341.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"5466_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.mayocp.2023.07.023","volume":"99","author":"C-Y Hsu","year":"2024","unstructured":"Hsu C-Y, et al. Efficacy of Sacubitril-Valsartan on survival and cardiac remodeling in hypotensive heart failure with reduced ejection fraction: A multicenter study. Mayo Clin Proc. 2024;99(6):940\u201352.","journal-title":"Mayo Clin Proc"},{"key":"5466_CR12","doi-asserted-by":"crossref","unstructured":"Bozkurt B, et al. Neprilysin inhibitors in heart failure: the Science, mechanism of Action, clinical Studies, and unanswered questions. JACC. Basic To Translational Science. 2022; 8(1):88-105.","DOI":"10.1016\/j.jacbts.2022.05.010"},{"key":"5466_CR13","doi-asserted-by":"publisher","first-page":"107210","DOI":"10.1016\/j.phrs.2024.107210","volume":"204","author":"D Nasrallah","year":"2024","unstructured":"Nasrallah D, et al. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction. Pharmacol Res. 2024;204:107210.","journal-title":"Pharmacol Res"},{"issue":"1","key":"5466_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12933-025-02741-5","volume":"24","author":"N Karuna","year":"2025","unstructured":"Karuna N, et al. Sacubitril\/Valsartan attenuates progression of diabetic cardiomyopathy through Immunomodulation properties: an opportunity to prevent progressive disease. Cardiovasc Diabetol. 2025;24(1):206.","journal-title":"Cardiovasc Diabetol"},{"key":"5466_CR15","doi-asserted-by":"crossref","unstructured":"Robles-Mezcua A, et al. Effects of sacubitril\/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: an integrated study of molecular biomarkers and imaging techniques. Biomedicine & Pharmacotherapy\u2009. 2025; 18 ; 117874.","DOI":"10.1016\/j.biopha.2025.117874"},{"issue":"6","key":"5466_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jchf.2024.12.010","volume":"13","author":"T Kondo","year":"2025","unstructured":"Kondo T, et al. Effects of Sacubitril\/Valsartan according to natriuretic peptide levels in patients enrolled in PARADIGM-HF and PARAGON-HF. JACC Heart Fail. 2025;13(6):927\u201339.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"5466_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ejhf.3454","volume":"27","author":"DV Nguyen","year":"2024","unstructured":"Nguyen DV, et al. Efficacy and safety of angiotensin receptor-neprilysin Inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis. Eur J Heart Fail. 2024;27(1):72\u201384.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"5466_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00392-022-02124-w","volume":"112","author":"M Fu","year":"2022","unstructured":"Fu M, et al. Real-world comparative effectiveness of ARNI versus ACEi\/ARB in HF with reduced or mildly reduced ejection fraction. Clin Res Cardiology: Official J German Cardiac Soc. 2022;112(1):167\u201374.","journal-title":"Clin Res Cardiology: Official J German Cardiac Soc"},{"issue":"1","key":"5466_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12931-025-03248-z","volume":"26","author":"W Li","year":"2025","unstructured":"Li W, et al. Angiotensin receptor blockers use and lung cancer risk in Chinese patients with chronic obstructive pulmonary disease: a population-based cohort study. Respir Res. 2025;26(1):186.","journal-title":"Respir Res"},{"key":"5466_CR20","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.intimp.2020.106507","volume":"84","author":"K Yang","year":"2020","unstructured":"Yang K, et al. Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma. Int Immunopharmacol. 2020;84:106507.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"5466_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ghir.2007.01.020","volume":"17","author":"M Petretta","year":"2007","unstructured":"Petretta M, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Hormone & IGF Research. Official J Growth Hormone Res Soc Int IGF Res Soc. 2007;17(4):288\u201396.","journal-title":"Official J Growth Hormone Res Soc Int IGF Res Soc"},{"key":"5466_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3389\/fphys.2018.00758","volume":"9","author":"C Sardu","year":"2018","unstructured":"Sardu C, et al. Stretch, injury and inflammation markers evaluation to predict clinical outcomes after implantable cardioverter defibrillator therapy in heart failure patients with metabolic syndrome. Front Physiol. 2018;9:758.","journal-title":"Front Physiol"},{"issue":"9","key":"5466_CR23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJV McMurray","year":"2013","unstructured":"McMurray JJV, et al. Dual angiotensin receptor and Neprilysin Inhibition as an alternative to angiotensin-converting enzyme Inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"5466_CR24","doi-asserted-by":"publisher","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, et al. Effects of the Angiotensin-Receptor Neprilysin inhibitor on cardiac reverse remodeling: Meta-Analysis. J Am Heart Association. 2019;8(13):e012272.","journal-title":"J Am Heart Association"},{"issue":"11","key":"5466_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jama.2019.12662","volume":"322","author":"MH Drazner","year":"2019","unstructured":"Drazner MH. Angiotensin Receptor-Neprilysin Inhibition (ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction. JAMA. 2019;322(11):1051\u20133.","journal-title":"JAMA"},{"key":"5466_CR26","doi-asserted-by":"crossref","unstructured":"Volpe M, Rubattu S, Battistoni A. ARNi: A novel approach to counteract cardiovascular diseases. Int J Mol Sci. 2019;20(9):2092-2104 .","DOI":"10.3390\/ijms20092092"},{"issue":"6","key":"5466_CR27","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ejhf.2191","volume":"23","author":"KS Jering","year":"2021","unstructured":"Jering KS, et al. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"5466_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","volume":"44","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Research: Official J Japanese Soc Hypertens. 2021;44(10):1239\u201350.","journal-title":"Hypertens Research: Official J Japanese Soc Hypertens"},{"issue":"7","key":"5466_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.2444","volume":"24","author":"I El-Battrawy","year":"2022","unstructured":"El-Battrawy I, Akin I. Impact of sacubitril\/valsartan on cardiac arrest event rate. Letter regarding the Article \u2018Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics\u2019. Eur J Heart Fail. 2022;24(7):1324.","journal-title":"Eur J Heart Fail"},{"key":"5466_CR30","doi-asserted-by":"crossref","unstructured":"Sutanto H, Dobrev D, Heijman J. Angiotensin Receptor-Neprilysin inhibitor (ARNI) and cardiac arrhythmias. Int J Mol Sci. 2021;22(16):8994-9007.","DOI":"10.3390\/ijms22168994"},{"issue":"8","key":"5466_CR31","doi-asserted-by":"publisher","first-page":"e029565","DOI":"10.1161\/JAHA.122.029565","volume":"12","author":"S Tsukamoto","year":"2023","unstructured":"Tsukamoto S, et al. Updates for Cardio-Kidney protective effects by angiotensin Receptor-Neprilysin inhibitor: requirement for additional evidence of kidney protection. J Am Heart Association. 2023;12(8):e029565.","journal-title":"J Am Heart Association"},{"key":"5466_CR32","doi-asserted-by":"publisher","first-page":"877237","DOI":"10.3389\/fmed.2022.877237","volume":"9","author":"L Gan","year":"2022","unstructured":"Gan L, et al. Application of angiotensin Receptor-Neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus. Front Med. 2022;9:877237.","journal-title":"Front Med"},{"issue":"1","key":"5466_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11886-018-0944-4","volume":"20","author":"K Kario","year":"2018","unstructured":"Kario K. The Sacubitril\/Valsartan, a First-in-Class, angiotensin receptor Neprilysin inhibitor (ARNI): potential uses in Hypertension, heart Failure, and beyond. Curr Cardiol Rep. 2018;20(1):5.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"5466_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ehjcvp\/pvv031","volume":"1","author":"V Katsi","year":"2015","unstructured":"Katsi V, et al. Angiotensin receptor Neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension? Eur Heart J Cardiovasc Pharmacotherapy. 2015;1(4):260\u20134.","journal-title":"Eur Heart J Cardiovasc Pharmacotherapy"},{"issue":"4","key":"5466_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/HJH.0000000000001223","volume":"35","author":"M Burnier","year":"2017","unstructured":"Burnier M. Is there a place for a dual angiotensin receptor-neprilysin inhibitor in the treatment of hypertension? J Hypertens. 2017;35(4):726\u20138.","journal-title":"J Hypertens"},{"issue":"29","key":"5466_CR36","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(29):3430\u20138.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5466_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","volume":"148","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto E, et al. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. Eur J Cancer (Oxford England: 1990). 2021;148:76\u201391.","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"issue":"11","key":"5466_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and Neprilysin Inhibition. Circulation. 2016;133(11):1115\u201324.","journal-title":"Circulation"},{"issue":"4","key":"5466_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","volume":"24","author":"Y Suematsu","year":"2018","unstructured":"Suematsu Y, et al. LCZ696 (Sacubitril\/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, attenuates cardiac Hypertrophy, Fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Card Fail. 2018;24(4):266\u201375.","journal-title":"J Card Fail"},{"key":"5466_CR40","doi-asserted-by":"publisher","first-page":"930797","DOI":"10.3389\/fcvm.2022.930797","volume":"9","author":"V Quagliariello","year":"2022","unstructured":"Quagliariello V, et al. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac damps Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front Cardiovasc Med. 2022;9:930797.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"5466_CR41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaccao.2020.09.007","volume":"2","author":"NE Boutagy","year":"2020","unstructured":"Boutagy NE, et al. Dual angiotensin Receptor-Neprilysin Inhibition with Sacubitril\/Valsartan attenuates systolic dysfunction in experimental Doxorubicin-Induced cardiotoxicity. JACC CardioOncology. 2020;2(5):774\u201387.","journal-title":"JACC CardioOncology"},{"key":"5466_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijcard.2020.06.041","volume":"318","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Sacubitril\/valsartan in the treatment of cancer therapy-related cardiac dysfunction. Int J Cardiol. 2020;318:130.","journal-title":"Int J Cardiol"},{"issue":"3","key":"5466_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.23736\/S0026-4806.22.08029-6","volume":"113","author":"AR Duraes","year":"2022","unstructured":"Duraes AR, et al. Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction: a systematic review of clinical and preclinical studies. Minerva Med. 2022;113(3):551\u20137.","journal-title":"Minerva Med"},{"issue":"7\u20138","key":"5466_CR44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.33963\/KP.a2022.0145","volume":"80","author":"G S\u0142awi\u0144ski","year":"2022","unstructured":"S\u0142awi\u0144ski G, et al. Effective cardioprotection with early initiation of Sacubitrilvalsartan in a patient with breast cancer and cancer treatment-induced heart failure. Kardiologia Polska. 2022;80(7\u20138):869\u201370.","journal-title":"Kardiologia Polska"},{"issue":"2","key":"5466_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ehf2.12627","volume":"7","author":"A Mart\u00edn-Garcia","year":"2020","unstructured":"Mart\u00edn-Garcia A, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020;7(2):763\u20137.","journal-title":"ESC Heart Fail"},{"key":"5466_CR46","first-page":"506","volume":"20","author":"M Hashemzehi","year":"2021","unstructured":"Hashemzehi M, et al. Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer. EXCLI J. 2021;20:506\u201321.","journal-title":"EXCLI J"},{"issue":"1","key":"5466_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159.","journal-title":"Mol Cancer"},{"issue":"1","key":"5466_CR48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12935-023-03080-9","volume":"23","author":"B Hassani","year":"2023","unstructured":"Hassani B, Attar Z, Firouzabadi N. The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies. Cancer Cell Int. 2023;23(1):254.","journal-title":"Cancer Cell Int"},{"key":"5466_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","volume":"108","author":"Y Xia","year":"2017","unstructured":"Xia Y, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138\u201348.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"5466_CR50","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1038\/s41598-022-09094-z","volume":"12","author":"T Miyoshi","year":"2022","unstructured":"Miyoshi T, et al. LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats. Sci Rep. 2022;12(1):4930.","journal-title":"Sci Rep"},{"key":"5466_CR51","doi-asserted-by":"crossref","unstructured":"Hu F, et al. Sacubitril\/valsartan attenuated myocardial inflammation, fibrosis, apoptosis and promoted autophagy in doxorubicin-induced cardiotoxicity mice via regulating the AMPK\u03b1-mTORC1 signaling pathway. Molecular and Cellular Biochemistry. 2024;480(3):1891-1908 .","DOI":"10.1007\/s11010-024-05117-7"},{"issue":"9","key":"5466_CR52","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/jpp\/rgad049","volume":"75","author":"MM Mahmoud Refaie","year":"2023","unstructured":"Mahmoud Refaie MM, et al. Sacubitril\/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF\/eNOS and TLR4\/TNF\u03b1\/IL6 signalling pathways. J Pharm Pharmacol. 2023;75(9):1237\u201348.","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"5466_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.31083\/j.rcm2407192","volume":"24","author":"L Cheng","year":"2023","unstructured":"Cheng L, et al. Sacubitril\/Valsartan ameliorates Crizotinib-Induced cardiotoxicity in mice. Rev Cardiovasc Med. 2023;24(7):192.","journal-title":"Rev Cardiovasc Med"},{"key":"5466_CR54","doi-asserted-by":"crossref","unstructured":"Mauriello A et al. Heart failure and wide QRS: clinical and Pharmacological perspectives. Biomedicines. 2025;13(6):1462-1475 .","DOI":"10.3390\/biomedicines13061462"},{"issue":"11","key":"5466_CR55","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/eurheartj\/ehi826","volume":"27","author":"NM Hawkins","year":"2006","unstructured":"Hawkins NM, et al. Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony? Eur Heart J. 2006;27(11):1270\u201381.","journal-title":"Eur Heart J"},{"issue":"6","key":"5466_CR56","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1002\/ehf2.14107","volume":"9","author":"H-T Huang","year":"2022","unstructured":"Huang H-T, et al. Clinical impacts of sacubitril\/valsartan on patients eligible for cardiac resynchronization therapy. ESC Heart Fail. 2022;9(6):3825\u201335.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"5466_CR57","first-page":"41","volume":"76","author":"LE Allam","year":"2024","unstructured":"Allam LE, et al. Unlocking the potential of sacubitril\/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF). Egypt Heart Journal: (EHJ) : Official Bull Egypt Soc Cardiol. 2024;76(1):41.","journal-title":"Egypt Heart Journal: (EHJ) : Official Bull Egypt Soc Cardiol"},{"issue":"4","key":"5466_CR58","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/FJC.0000000000001202","volume":"79","author":"V Russo","year":"2022","unstructured":"Russo V, et al. Add-on therapy with Sacubitril\/Valsartan and clinical outcomes in CRT-D nonresponder patients. J Cardiovasc Pharmacol. 2022;79(4):472\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"5466_CR59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jchf.2020.09.014","volume":"9","author":"MS Khan","year":"2020","unstructured":"Khan MS, et al. Reverse cardiac remodeling following initiation of Sacubitril\/Valsartan in patients with heart failure with and without diabetes. JACC Heart Fail. 2020;9(2):137\u201345.","journal-title":"JACC Heart Fail"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05466-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:02:45Z","timestamp":1767690165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05466-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5466"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05466-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}